U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H19ClFN7
Molecular Weight 387.842
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FALNIDAMOL

SMILES

CN1CCC(CC1)NC2=NC3=C(C=N2)N=CN=C3NC4=CC(Cl)=C(F)C=C4

InChI

InChIKey=FTFRZXFNZVCRSK-UHFFFAOYSA-N
InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)

HIDE SMILES / InChI
Molecular Formula C18H19ClFN7
Molecular Weight 387.842
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Falnidamol is an epidermal growth factor receptor inhibitor, developed by Boehringer Ingelheim. Falnidamol demonstrated anticancer activity in vitro. The phase I trial was discontinued due to a dose-limiting increase of liver enzymes, low bioavailability of the drug and the detection of a pharmacologically inactive metabolite.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Epidermal growth factor receptor
49
Target ID: P00533|||Q9GZX1
Gene ID: 1956.0
Gene Symbol: EGFR
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 3.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.009 ng/mL
REVIEW
https://www.ejcancer.com/article/S0959-8049(02)00020-5/fulltext
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALNIDAMOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.16 ng/mL
REVIEW
https://www.ejcancer.com/article/S0959-8049(02)00020-5/fulltext
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALNIDAMOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.036 ng × h/mL
REVIEW
https://www.ejcancer.com/article/S0959-8049(02)00020-5/fulltext
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALNIDAMOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.97 ng × h/mL
REVIEW
https://www.ejcancer.com/article/S0959-8049(02)00020-5/fulltext
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALNIDAMOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
REVIEW
https://www.ejcancer.com/article/S0959-8049(02)00020-5/fulltext
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALNIDAMOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.3 h
REVIEW
https://www.ejcancer.com/article/S0959-8049(02)00020-5/fulltext
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALNIDAMOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1388

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 inconclusive [IC50 25.929 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1388
 major
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00ABZS
https://www.1pchem.com/search?query=1P00ABZS
AChemBlock
10233
http://www.achemblock.com/catalogsearch/result/?q=10233
AK Scientific
SYN5568
https://aksci.com/item_detail.php?cat=SYN5568
Angene
AGN-PC-0WHA07
http://www.angenechemical.com/productshow/AGN-PC-0WHA07.html
AOBIOUS INC
AOB5489
http://aobious.com/aobious/search?search_query=AOB5489
ApexBio Technology
A3240
https://www.apexbt.com/catalogsearch/result/?q=A3240
AstaTech
40762
http://astatechinc.com/CPSResult.php?CRNO=40762
BLD Pharm
BD303668
http://www.bldpharm.com/search/Search.html?keyword=BD303668
BOC Sciences
196612-93-8
http://www.bocsci.com/description.asp?cas=196612-93-8
Chem Scene
CS-0691
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0691
ChemShuttle
134406
https://www.chemshuttle.com/catalogsearch/result/?q=134406
Debye Scientific
DB-014915
https://www.debyesci.com/index.php?id=product&ext[cno]=DB-014915
eMolecules
17400145
https://orderbb.emolecules.com/search/#?query=17400145
eMolecules
300117866
https://orderbb.emolecules.com/search/#?query=300117866
eMolecules
44811572
https://orderbb.emolecules.com/search/#?query=44811572
Excenen
EX-A570
http://www.excenen.com/searchresultlist.php?id=EX-A570
Exclusive Chemistry
2387
http://www.exchemistry.com/chem-catalog/product-2387.html
KeyOrganics
AS-16894
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16894
Lab Network
LN01299307
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01299307
Matrix Scientific
153988
http://www.matrixscientific.com/153988.html
mcule
MCULE-6165916754
https://mcule.com/MCULE-6165916754/
MedChem Express
HY-10322
https://www.medchemexpress.com/search.html?q=HY-10322&ft=&fa=&fp=
MolPort
MolPort-021-783-059
https://www.molport.com/shop/molecule-link/MolPort-021-783-059
MolPort
MolPort-039-136-623
https://www.molport.com/shop/molecule-link/MolPort-039-136-623
MuseChem
I010550
https://www.musechem.com/product/I010550.html
ShangHai Biochempartner
BCP001133
http://www.biochempartner.com/search_BCP001133
ShangHai Biochempartner
BCP09515
http://www.biochempartner.com/search_BCP09515
Tocris
2416
https://www.tocris.com/search.php?Type=QuickSearch&Value=2416
Wonderchem
WD05IQU
http://www.wonder-chem.com/search.html?text=WD05IQU
PubMed

PubMed

TitleDatePubMed
Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.
2004-11
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.
2002-05
In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.
2000-01-25
Patents

Patents

EP1300146 A1
1
US5821240 A
1
WO2002002120 A1
1

Sample Use Guides

In Vivo Use Guide
In a phase I study, patients received falnidamol orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 150 mg.
Route of Administration: Oral
In Vitro Use Guide
T47D cells were treated with falnidamol at 0.01, 0.03, 0.1, 0.3, 1, 3, 10 uM for 1 h. 3 uM of the drug was sufficient to block signaling by TGF-alpha. 10 uM falnidamol blocked ErbB2 activity efficiently.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:24:18 GMT 2025
Edited
by admin
on Mon Mar 31 18:24:18 GMT 2025
Record UNII
0MU316797D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FALNIDAMOL
INN   WHO-DD  
INN  
Official Name English
BIBX 1382
Preferred Name English
BIBX1382
Common Name English
Falnidamol [WHO-DD]
Common Name English
8-(3-CHLORO-4-FLUOROANILINO)-2-((1-METHYL-4-PIPERIDYL)AMINO)PYRIMIDO(5,4-D)PYRIMIDINE
Systematic Name English
BIBX-1382
Code English
falnidamol [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2167
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
NCI_THESAURUS C1967
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
Code System Code Type Description
SMS_ID
100000127711
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
CAS
196612-93-8
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
EVMPD
SUB33798
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
FDA UNII
0MU316797D
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
INN
7857
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
DRUG BANK
DB12966
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
PUBCHEM
6918508
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
NCI_THESAURUS
C80868
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
ChEMBL
CHEMBL258940
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
EPA CompTox
DTXSID0048399
Created by admin on Mon Mar 31 18:24:18 GMT 2025 , Edited by admin on Mon Mar 31 18:24:18 GMT 2025
PRIMARY
Related Record Type Details
ALDEHYDE OXIDASE
METABOLIC ENZYME -> SUBSTRATE
Failed due to undetected hAOX-mediated oxidation.
EPIDERMAL GROWTH FACTOR RECEPTOR
TARGET -> INHIBITOR
Related Record Type Details
Structure of 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1-methylpiperidin-4-yl)amino]-2H,3H-[1,3]diazino[5,4-d]pyrimidin-2-one
METABOLITE -> PARENT
Related Record Type Details
Structure of FALNIDAMOL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966